New vaccine strategy aims to stop Cancer's return
NCT ID NCT05350501
Summary
This study tested a new type of vaccine, EO2040, combined with an immunotherapy drug (nivolumab). It aimed to prevent colorectal cancer from returning in patients who had finished standard treatment but still had tiny traces of cancer DNA in their blood. The trial was terminated early after enrolling only one participant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.